Get started
AbbVie Inc.AbbVie Inc.AbbVie Inc.

AbbVie Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

ABBV trade ideas

If ABBV chooses to decline, we are ready.AbbVie - 30d expiry - We look to Sell a break of 132.58 (stop at 137.03) 133 continues to hold back the bears. 132.75 has been pivotal. Posted a Double Bottom formation. A break of the recent low at 132.74 should result in a further move lower. Our profit targets will be 121.01 and 117.01 Resistance: 154 / 157 / 160 Support: 147 / 142 / 137 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:ABBVShort
by Saxo
1
ABBV | Bull Flag Formation | LONGNYSE:ABBV AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
NYSE:ABBVLong
by DivergenceSeeker
IS $ABBV ready to come up on the right side of its base?Notes: * Strong up trend on all time frames * Great earnings track record * Basing for the past ~8 months * Now looking to come up on the right side of its base * Printed a pocket pivot in the last session, indicating institutional buying * Offering an early entry relative to its 50 day line Technicals: Sector: Healthcare - Drug Manufacturers - General Relative Strength vs. Sector: 6.46 Relative Strength vs. SP500: 2.33 U/D Ratio: 1.4 Base Depth: 28.76% Distance from breakout buy point: -12.22% Volume 18.24% above its 15 day avg. Trade Idea: * You can enter now as the price is coming off of its 50 day line * If you're looking for a better entry you can look for one around the ~147 area as that should hold as support moving forward * If you're looking for a safer entry you can wait for a break and close above the ~152.5 area as that is the immediate resistance coming up * A daily close below the ~147 area would negate the bullish outlook.
NYSE:ABBVLong
by HaseebKhan_90
Waterfall on AbbVie. ABBVBetting on a further crash in AbbVie stock price. That huge candle preempts formal volatility switch. Fractally, hard to tell from this picture, possibly a start of a C in a WXY pattern. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:ABBVShort
by Rykin_Capital
AbbVie. Waiting for an exit from uptrendAbbVie Inc. Idea: Long Horizon: 1-2 months Target: $145 Entry range: $143-145 Stop order: $141 Technical analysis The share price has formed a short-term uptrend. If the local resistance level is broken through, there is a potential to move higher. Idea to increase the stock with the target of $145. Fundamental factor AbbVie is an American biopharmaceutical company founded in 2013 by a spinoff from Abbott Laboratories. One of the largest pharmaceutical companies in the world. Healthcare is a classic defensive sector in times of stock market turbulence. Given the high likelihood of continued serious tightening of monetary policy by the Fed, investors are shifting funds from interest-rate-dependent sectors to more stable ones. AbbVie's broadly diversified portfolio of drugs and products makes it one of the best candidates for this strategy.
NYSE:ABBVLong
by SiriusBH
Falling Wedge on the dailyOur AbbVie is trying to break out of the "Falling Wedge" pattern but is having a hard time. Despite the pattern resistance being broken, momentum is weakening (MACD). In addition, the volume is nearly average. It is the opposite of what we want to see when we expect a breakout from a 222-day pattern. It is probably due to bearish market sentiment. Given the situation, I have marked the two possible scenarios on the graph. 1. Scenario: overall market turns bullish. In this case, there is a chance for continuation with a target price of 151.72. 2. Scenario: market keeps dipping. I expect a false outbreak. In this case, we could easily visit the 131.18 level. Support: 141.88, 141, 137.55, 131.18 Resistance: 147.4, 150.78, 151.87
NYSE:ABBV
by benedekdomotor
1
Equity Seasonality and Bear Market Sector and Stock Selection Seasonalities are regular and predictable patterns that recur every calendar year. Every industry exhibits unique seasonal trends that are based on fundamental drivers. The best-known seasonal drivers include harvest periods, the timing of interest payments, weather, and investor sentiment. At certain times of the year, tax and balance sheet deadlines, annual or quarterly financial reports, as well as traditional patterns, such as the year-end rally in the stock market all create regular seasonal tendencies. These patterns occur across individual equities, commodities, and indices. Statistical analysis of these seasonal trends and patterns can be an extremely important part of a trading approach. In this piece, we combine this seasonal approach with our approach to sector investing in bear markets to provide examples. When the S&P 500 hit bear market territory on June 13 2022, many investors were left with the bitter taste of disappointment. But this wasn’t happening for the first time: since 1928, the S&P 500 has experienced 26 bear markets. “Bears” are part of normal market trends. They are relatively short in duration (especially compared with bull markets), and can provide good investment opportunities. They come into existence when a market falls by at least 20% from recent highs. In our process, we combine balance sheet analysis, sector selection and seasonality. During bear markets, it’s important to concentrate on good balance sheets in “recession-proof” sectors. Most stocks suffer during a recession, but there are sectors that are much more likely to outperform the broad market. In my previous Seasonal Insights, I have discussed luxury stocks (these insight pieces are available on our website) that have proven their strength during difficult times. It is an industry that resists crises: luxury customers, due to their financial wealth, recover very quickly. Stocks that tend to outperform during bear markets can be found in defensive sectors, such as consumer staples, utilities and healthcare. Healthcare is a great example of a haven. One of the stocks to consider from this sector is pharmaceutical giant AbbVie. AbbVie is known as a “low-volatility dividend aristocrat.” This posh expression refers to a group of high-quality S&P 500 stocks recognized for delivering at least 25 straight years of dividend growth. If you decide to enter this trade you should consider its seasonality. Seasonality will offer you the best entry and exit points for a specific stock during the year. It will also prevent you from investing in a name that is entering a seasonally weak period. Keep in mind that a seasonal chart depicts the average price pattern of a stock over the course of a calendar year. It is calculated over several years (unlike a standard price chart that simply shows stock prices over a specific time period). The horizontal axis depicts the time of the year, while the vertical axis shows the level of the seasonal pattern (indexed to 100). From the chart above, it is clearly visible that the end of October until the end of December, over the past 9 years, have been favorable months for this health stock. In this time span of 46 trading days (from October 24 until December 30), shares rose on average by almost 14%. Moreover, since 2013 the pattern returns had a winning strike of 100%, meaning that AbbVie Inc generated gain each year since 2013 during the selected time period. There are also other stocks that are trending high in this sector, such as Pfizer, Eli Lilly, or even insurances like United Health, Anthem and Centene. Another consequence of a recession is that many consumers will curb their spending. However, consumers still need to buy staples such as food, household goods and hygiene items. Demand for these tend to hold up better than other areas of the economy. Large food manufacturers such as Tyson Foods, Kellogg and Mondelez International all fall into this category as do large agribusinesses that focus on the raw materials used in food production, such as Bunge or Archer-Daniels Midland. During difficult times, consumers also tend to look for cheaper alternatives from discount retailers. Even if people shop less during a downturn, they still need to buy staples, and are more likely to treat themselves to a cheaper item at a discount store. Dollar Tree was the best performer in the S&P 500 during the 2008 financial crisis, and was up significantly that year even as the overall market plummeted. There are also personal care and household product manufacturers such as Colgate-Palmolive and Procter & Gamble. All these stocks suffered a smaller decline than other areas of the stock market during the 2008 financial crash and most of them bottomed out months before the broad market. But still be aware of the investment timing. Each stock mentioned here has its strong and weak periods during the year. For instance, Kellogg is worth considering after the August – September period of weakness. Remember, for every bear market, a bull market follows. Yours sincerely, Tea Muratovic Co-Founder and Managing Partner of Seasonax Guest Author for CMT Association seasonax.com Many of the topics and techniques discussed in this post are part of the CMT Associations Chartered Market Technician’s curriculum. Shared content and posted charts are intended to be used for informational and educational purposes only. The CMT Association does not offer, and this information shall not be understood or construed as, financial advice or investment recommendations. The information provided is not a substitute for advice from an investment professional. The CMT Association does not accept liability for any financial loss or damage our audience may incur.
NYSE:ABBV
by CMT_Association
10